Quick Answer
NRX Pharmaceuticals, Inc. reported Diluted EPS of $0.60 per share (loss) for fiscal year 2022.
NRX Pharmaceuticals, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2022 | -$0.60 | +69.7% |
| 2021 | -$1.98 | -31.1% |
| 2020 | -$1.51 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| March 31, 2024 | -$0.74 | +55.4% | -957.1% |
| September 30, 2023 | -$0.07 | +50.0% | +41.7% |
| June 30, 2023 | -$0.12 | -9.1% | +92.8% |
| March 31, 2023 | -$1.66 | -690.5% | -1085.7% |
| September 30, 2022 | -$0.14 | +80.6% | -27.3% |
| June 30, 2022 | -$0.11 | +73.2% | +47.6% |
| March 31, 2022 | -$0.21 | +70.4% | +70.8% |
| September 30, 2021 | -$0.72 | -380.0% | -75.6% |
- NRX Pharmaceuticals, Inc. showed an increase of +69.7% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2022 period, NRX Pharmaceuticals, Inc.’s diluted eps has grown by 60.3% (from $1.51 per share (loss) to $0.60 per share (loss)).
- The most recent figure is from NRX Pharmaceuticals, Inc.’s fiscal year 2022 report (Form 10-K), filed with the SEC on March 31, 2023.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: